1.	Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 3144A2-3004, B1891004, NCT00878709
2.	A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 3144A1-202, B1891013, NCT00398567
3.	A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 3144A1-203, B1891014, NCT00445458
4.	Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 3144A1-2204, B1891015, NCT00706030
5.	Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 3144A1-2206, B1891017, NCT00741260
6.	Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 3144A1-200, B1891037, NCT00266877
7.	Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 3144A1-201, B1891012, NCT00300781
8.	Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 3144A2-3003, B1891003, NCT00777101
9.	Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 3144A2-3005, B1891005, NCT00915018
10.	Study Evaluating HKI-272 in Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 3144A1-102, NCT00146172
11.	A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 20 and over Sponsor: Other Protocol IDs: 3144A1-104, NCT00397046
12.	Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization) Phase: Phase I Type: Supportive care, Treatment Status: Completed Age: 18 to 50 Sponsor: Other Protocol IDs: 3144A1-105, NCT00708903
13.	Study Evaluating Safety And Tolerability, Solid Tumor Phase: Phase I Type: Treatment Status: Completed Age: 20 and over Sponsor: Other Protocol IDs: 3144A2-1115, B1891001, NCT00768469
14.	Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 3144A1-2205, B1891016, NCT00838539
15.	Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 20 and over Sponsor: Other Protocol IDs: 3144A2-1118, B1891002, NCT00958724
16.	A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 20 and over Sponsor: Other Protocol IDs: 3144A1-1122, B1891018, NCT01128842
17.	Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: NSABP FB-8, WS1554503, NCT01423123